vs

Side-by-side financial comparison of EVI INDUSTRIES, INC. (EVI) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $115.3M, roughly 1.3× EVI INDUSTRIES, INC.). EVI INDUSTRIES, INC. runs the higher net margin — 2.1% vs -5.5%, a 7.6% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 24.4%). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 17.2%).

EVI Industries, Inc. is a leading distributor of commercial laundry, dry cleaning, and garment care equipment, as well as related parts and supplies. It primarily serves commercial customers across North America, including laundromats, hospitality businesses, healthcare facilities, and multi-family housing properties, offering installation, maintenance and after-sales support services.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

EVI vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.3× larger
TARS
$151.7M
$115.3M
EVI
Growing faster (revenue YoY)
TARS
TARS
+104.0% gap
TARS
128.4%
24.4%
EVI
Higher net margin
EVI
EVI
7.6% more per $
EVI
2.1%
-5.5%
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
17.2%
EVI

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
EVI
EVI
TARS
TARS
Revenue
$115.3M
$151.7M
Net Profit
$2.4M
$-8.4M
Gross Margin
30.8%
Operating Margin
3.7%
-5.3%
Net Margin
2.1%
-5.5%
Revenue YoY
24.4%
128.4%
Net Profit YoY
109.9%
63.8%
EPS (diluted)
$0.15
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EVI
EVI
TARS
TARS
Q4 25
$115.3M
$151.7M
Q3 25
$108.3M
$118.7M
Q2 25
$110.0M
$102.7M
Q1 25
$93.5M
$78.3M
Q4 24
$92.7M
$66.4M
Q3 24
$93.6M
$48.1M
Q2 24
$90.1M
$40.8M
Q1 24
$84.0M
$27.6M
Net Profit
EVI
EVI
TARS
TARS
Q4 25
$2.4M
$-8.4M
Q3 25
$1.8M
$-12.6M
Q2 25
$2.1M
$-20.3M
Q1 25
$1.0M
$-25.1M
Q4 24
$1.1M
$-23.1M
Q3 24
$3.2M
$-23.4M
Q2 24
$2.1M
$-33.3M
Q1 24
$956.0K
$-35.7M
Gross Margin
EVI
EVI
TARS
TARS
Q4 25
30.8%
Q3 25
31.3%
Q2 25
30.8%
Q1 25
30.0%
Q4 24
29.7%
Q3 24
30.8%
Q2 24
30.4%
Q1 24
30.7%
Operating Margin
EVI
EVI
TARS
TARS
Q4 25
3.7%
-5.3%
Q3 25
3.3%
-12.2%
Q2 25
3.7%
-21.6%
Q1 25
2.4%
-33.5%
Q4 24
2.6%
-36.8%
Q3 24
5.3%
-52.3%
Q2 24
4.1%
-81.6%
Q1 24
2.9%
-136.5%
Net Margin
EVI
EVI
TARS
TARS
Q4 25
2.1%
-5.5%
Q3 25
1.7%
-10.6%
Q2 25
1.9%
-19.8%
Q1 25
1.1%
-32.1%
Q4 24
1.2%
-34.8%
Q3 24
3.5%
-48.7%
Q2 24
2.3%
-81.6%
Q1 24
1.1%
-129.4%
EPS (diluted)
EVI
EVI
TARS
TARS
Q4 25
$0.15
$-0.17
Q3 25
$0.11
$-0.30
Q2 25
$0.14
$-0.48
Q1 25
$0.07
$-0.64
Q4 24
$0.07
$-0.57
Q3 24
$0.21
$-0.61
Q2 24
$0.13
$-0.88
Q1 24
$0.06
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EVI
EVI
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$144.0M
$343.4M
Total Assets
$315.6M
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EVI
EVI
TARS
TARS
Q4 25
$417.3M
Q3 25
$4.7M
$401.8M
Q2 25
$8.9M
$381.1M
Q1 25
$5.9M
$407.9M
Q4 24
$3.9M
$291.4M
Q3 24
$4.4M
$317.0M
Q2 24
$4.6M
$323.6M
Q1 24
$3.3M
$298.5M
Total Debt
EVI
EVI
TARS
TARS
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$24.0M
$72.0M
Q4 24
$27.9M
$71.8M
Q3 24
$19.9M
$71.7M
Q2 24
$12.9M
$71.6M
Q1 24
$21.9M
$29.9M
Stockholders' Equity
EVI
EVI
TARS
TARS
Q4 25
$144.0M
$343.4M
Q3 25
$140.8M
$335.1M
Q2 25
$143.5M
$332.6M
Q1 25
$140.2M
$342.5M
Q4 24
$138.0M
$224.5M
Q3 24
$136.1M
$237.5M
Q2 24
$136.6M
$252.2M
Q1 24
$133.5M
$275.2M
Total Assets
EVI
EVI
TARS
TARS
Q4 25
$315.6M
$562.2M
Q3 25
$321.8M
$534.6M
Q2 25
$307.0M
$495.0M
Q1 25
$251.8M
$500.8M
Q4 24
$248.8M
$377.0M
Q3 24
$245.5M
$376.3M
Q2 24
$230.7M
$376.8M
Q1 24
$239.3M
$349.3M
Debt / Equity
EVI
EVI
TARS
TARS
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.17×
0.21×
Q4 24
0.20×
0.32×
Q3 24
0.15×
0.30×
Q2 24
0.09×
0.28×
Q1 24
0.16×
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EVI
EVI
TARS
TARS
Operating Cash FlowLast quarter
$4.0M
$19.3M
Free Cash FlowOCF − Capex
$13.0M
FCF MarginFCF / Revenue
8.6%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
1.70×
TTM Free Cash FlowTrailing 4 quarters
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EVI
EVI
TARS
TARS
Q4 25
$4.0M
$19.3M
Q3 25
$1.0M
$18.3M
Q2 25
$9.9M
$-29.4M
Q1 25
$9.1M
$-20.7M
Q4 24
$2.0M
$-22.2M
Q3 24
$207.0K
$-8.7M
Q2 24
$12.4M
$-14.4M
Q1 24
$9.4M
$-37.8M
Free Cash Flow
EVI
EVI
TARS
TARS
Q4 25
$13.0M
Q3 25
$-890.0K
$16.3M
Q2 25
$8.2M
$-30.4M
Q1 25
$8.1M
$-21.2M
Q4 24
$1.1M
$-22.3M
Q3 24
$-1.0M
$-8.9M
Q2 24
$11.2M
$-15.4M
Q1 24
$8.1M
$-38.0M
FCF Margin
EVI
EVI
TARS
TARS
Q4 25
8.6%
Q3 25
-0.8%
13.8%
Q2 25
7.5%
-29.6%
Q1 25
8.7%
-27.1%
Q4 24
1.2%
-33.5%
Q3 24
-1.1%
-18.6%
Q2 24
12.4%
-37.8%
Q1 24
9.7%
-137.5%
Capex Intensity
EVI
EVI
TARS
TARS
Q4 25
4.2%
Q3 25
1.8%
1.6%
Q2 25
1.5%
1.0%
Q1 25
1.1%
0.8%
Q4 24
0.9%
0.1%
Q3 24
1.3%
0.6%
Q2 24
1.3%
2.5%
Q1 24
1.5%
0.6%
Cash Conversion
EVI
EVI
TARS
TARS
Q4 25
1.70×
Q3 25
0.55×
Q2 25
4.74×
Q1 25
8.79×
Q4 24
1.74×
Q3 24
0.06×
Q2 24
5.99×
Q1 24
9.85×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons